Noble Secures New Patent for AI-Powered Sound Detection in Drug Delivery and Diagnostic Devices
New patent helps verify correct device operation, which may support patient confidence and adherence through AI-enabled performance feedback
Noble, an Aptar Pharma company providing patient-centered solutions that support the safe and effective use of drug delivery and diagnostic devices, today announced the issuance of a new U.S. patent covering an artificial intelligence-enabled method for detecting, analyzing and classifying sound output from drug delivery and diagnostic devices. The patented approach advances training, verification and performance feedback by objectively determining whether a device has been operated correctly.
The technology can help determine whether critical device-use steps were completed successfully, providing objective feedback to indicate whether a user has correctly operated a device. As more therapies move into the home and self-administration becomes increasingly common, understanding whether a patient has successfully used a device is becoming an important component of supporting adherence and confidence.
"At Aptar Pharma, the patient remains at the center of everything we do," said Craig Baker, President of Noble, an Aptar Pharma company. "This patent reflects our commitment to applying artificial intelligence in ways that help patients use therapies more confidently and consistently. By recognizing and classifying sounds generated during device operation, this technology can help determine whether critical steps were completed correctly, providing objective feedback that supports correct device use."
